Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Tarsus Pharmaceuticals's total debt was $72.76M at Jun 30, 2026. For fiscal 2025 it was $72.44M, up 0.8% from the year before. The highest annual figure on record is $72.44M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.44M | +0.8% |
| FY2024 | Dec 31, 2024 | $71.85M | +140.9% |
| FY2023 | Dec 31, 2023 | $29.82M | +53.4% |
| FY2022 | Dec 31, 2022 | $19.43M | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $72.76M | +0.9% |
| Q1 FY2026 | Mar 31, 2026 | $72.60M | +0.9% |
| Q4 FY2025 | Dec 31, 2025 | $72.44M | +0.8% |
| Q3 FY2025 | Sep 30, 2025 | $72.28M | +0.8% |
| Q2 FY2025 | Jun 30, 2025 | $72.13M | +0.8% |
| Q1 FY2025 | Mar 31, 2025 | $71.98M | +140.5% |
| Q4 FY2024 | Dec 31, 2024 | $71.85M | +140.9% |
| Q3 FY2024 | Sep 30, 2024 | $71.71M | +141.4% |
| Q2 FY2024 | Jun 30, 2024 | $71.58M | +190.9% |
| Q1 FY2024 | Mar 31, 2024 | $29.93M | +22.1% |
| Q4 FY2023 | Dec 31, 2023 | $29.82M | +53.4% |
| Q3 FY2023 | Sep 30, 2023 | $29.71M | +53.5% |
| Q2 FY2023 | Jun 30, 2023 | $24.61M | +27.7% |
| Q1 FY2023 | Mar 31, 2023 | $24.52M | +27.8% |
| Q4 FY2022 | Dec 31, 2022 | $19.43M | – |
| Q3 FY2022 | Sep 30, 2022 | $19.36M | – |
| Q2 FY2022 | Jun 30, 2022 | $19.26M | – |
| Q1 FY2022 | Mar 31, 2022 | $19.18M | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
See a number that looks wrong?